Trial abstracts in the registry
700 documents of type trial abstract.
Documents
-
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low19 Jul 2026 -
Event-driven cardiovascular outcome trial, phase 3 study of Survodutide in cardiovascular and obesity over event-driven. The Institute holds no reported primary result…
11 Jul 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over 76 weeks. The Institute holds no reported primary result…
26 Jun 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low15 Jun 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low22 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low17 May 2026 -
Randomised, double-blind, active-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over 72 weeks. The Institute holds no reported primary…
14 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in knee osteoarthritis and obesity over as stated in the parent protocol. The Institute holds…
Very low13 May 2026 -
Randomised crossover, phase 1 study of Tirzepatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low10 May 2026 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low08 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low05 May 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over 40 weeks. The Institute holds no reported primary result for this…
03 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Apr 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low22 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
20 Mar 2026 -
Phase 1 ascending dose, phase 1 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute holds no reported…
Very low20 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over 76 weeks. The Institute holds no reported primary result for this record and…
19 Mar 2026 -
Single-arm open-label, phase 3 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low19 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 2 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low19 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Orforglipron in type 2 diabetes over 52 weeks. The Institute holds no reported primary result for this…
18 Mar 2026 -
Single-arm open-label, phase 3 study of Retatrutide in sleep apnoea over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low18 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Ecnoglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low17 Mar 2026 -
Observational, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low16 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over 68 weeks or longer. The Institute holds no reported…
13 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low13 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low10 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over 52 weeks. The Institute holds no reported primary result for…
06 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over 68 weeks or longer. The Institute holds no reported…
03 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low03 Mar 2026 -
Randomised crossover, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low03 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
02 Mar 2026 -
Observational, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low02 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Mar 2026 -
Randomised crossover, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low01 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Feb 2026
page 1 of 18